If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  Scientists Find Marker that Signals Better Survival for Children with Brain Cancer LONDON, UK -- October 28, 2005 -- Scientists supported by Cancer Research UK and the Samantha Dickson Research Trust have uncovered a protein that signals a more favourable survival for children with a form of childhood brain tumour, reveals a study published today (Friday) in the Journal of Clinical Oncology*. Researchers from the University of Newcastle upon Tyne, who are members of the United Kingdom Children's Cancer Study Group (UKCCSG), studied the tumour cells of 109 patients with a form of malignant childhood brain tumour called medulloblastoma. The results from the European-wide trial** revealed that 25 per cent of the tumours showed activation of a protein called Beta-catenin. The 27 patients with this protein had a survival rate of nearly 93 per cent, compared to 65 per cent for patients without it. Treatments for childhood brain tumours are intensive and can have difficult side effects. Understanding more about how a tumour is likely to behave may allow doctors to tailor treatments to better suit individual children. The researchers believe that patients who carry the activated protein have a milder form of the disease and could be spared unnecessary treatment. This could reduce the impact of side effects on patients' later life. For children with more aggressive tumours, intensive therapies could be prescribed earlier to try to improve these patients' outcome. Study author David Ellison, Professor of Neuropathology at Newcastle University's Northern Institute for Cancer Research, says: "This is the first time that a protein has been identified which signals a more favourable outcome in childhood medulloblastoma. We hope this discovery will make a crucial difference for patients having treatment for this type of brain tumour in the future. "What was surprising about our results is that the catenin protein had previously been shown to be associated with aggressive behaviour in other cancers. In contrast we found that it was such a strong marker of positive outcome in medulloblastoma that even those patients whose cancer had been diagnosed at a later stage, when it had spread, had a more favourable outcome than those patients who lacked the activated protein." Professor John Toy, Medical Director of Cancer Research UK, says: "The management of childhood brain tumours will only improve with a greater understanding of the disease and these researchers have made an important contribution to identifying how these tumours respond to treatment. The research was supported by grants from the Samantha Dickson Research Trust, the Faculty of Medical Sciences, University of Newcastle upon Tyne, and through Cancer Research UK's support for the UKCCSG. In the UK, about 300 children are diagnosed with a brain tumour each year. Medulloblastoma is the most common malignant brain cancer in children, making up around 20 per cent of all cases. Currently around 40 per cent of affected children die of the disease. Cells in the developing nervous system, which normally form the cerebellum or hind-brain, can sometimes turn cancerous to form a medulloblastoma. Tumours that develop from these early cells are called PNETs (Primitive NeuroEctodermal Tumours), and medulloblastoma is the commonest type of PNET. *Beta-catenin status predicts a favourable outcome in childhood medulloblastoma. Journal of Clinical Oncology. David W Ellison, Olabisi E Onilude, Janet C Lindsey, Meryl E Lusher, Claire L Weston, Roger E Taylor, Andrew D Pearson and Steven C Clifford. Volume 24, Issue 31. **Results from the SIOP (International Society of Paediatric Oncology)/UKCCSG
SOURCE: Cancer Research UK
|
